A Double-blind, Randomized Phase 2 Controlled Trial of Intradermal Hepatitis B Vaccination With a Topical Toll-like Receptor 7 Agonist Imiquimod, in Patients on Dialysis

Clicks: 173
ID: 111103
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #304 of 1,084 articles by views in clinical infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
This study demonstrated that topical imiquimod (TLR7 agonist) before intradermal hepatitis B vaccination was safe, with significantly better seroprotection than
Reference Key
fan-ngaiclinicala Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hung, Ivan Fan-Ngai;Yap, Desmond Yat-Hin;Yip, Terence Pok-Siu;Zhang, Ricky Ruiqi;To, Kelvin Kai-Wang;Chan, Kwok-Hung;Tang, Sydney Chi-Wai;Lui, Sing-Leung;Levin, Yotam;Kochba, Efrat;Lau, Johnson Yiu-Nam;Yuen, Man-Fung;Chan, Tak-Mao;Yuen, Kwok-Yung;
Journal clinical infectious diseases
Year Year not found
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.